NurExone Biologic Inc. (NRXBF) news focuses on its progress as a preclinical biotechnology company developing regenerative exosome-based therapies for central nervous system injuries. The company’s updates highlight advances in its lead candidate ExoPTEN, exosome manufacturing capabilities, regulatory milestones, intellectual property, and financing activities that support its development plans.
Readers following NurExone’s news can see detailed reports on preclinical data, including dose-dependent recovery of visual function in glaucoma and optic nerve injury models and motor recovery in acute spinal cord injury models. The company also publishes laboratory analyses showing anti-inflammatory activity of its exosomes and higher biological activity compared with commercially available exosome products, which it presents as strengthening the rationale for its platform.
News releases also cover regulatory and scientific visibility, such as Orphan Drug Designation for ExoPTEN in acute spinal cord injury and invited presentations at international conferences on exosomes, regenerative medicine, and bioprocessing. These items provide insight into how NurExone is engaging with regulators and the scientific community around exosome-based therapeutics.
On the corporate side, NurExone reports on patent developments, including a U.S. Notice of Allowance and an Israeli patent grant for its exosome manufacturing process, as well as its participation in programs like ARMI’s BioFab Startup Lab. Investors can also track capital raises, warrant exercises, and private placements that fund R&D, manufacturing initiatives, and U.S. expansion through its subsidiary Exo-Top Inc., including plans for a commercial exosome production facility in Indianapolis, Indiana.
For anyone monitoring NRXBF, this news stream offers a consolidated view of scientific results, manufacturing readiness, regulatory positioning, and financial developments that shape NurExone’s trajectory in exosome-based CNS therapies.
NurExone (OTCQB: NRXBF) announced a bioprocess optimization initiative with Austria-based Novasign to support manufacturing infrastructure for its exosome-based therapeutic pipeline and commercial activities. Novasign’s bioprocess modeling platform, Novasign Studio, will be applied to NurExone’s proprietary exosome production process to analyze upstream bioprocess data against predefined KPIs such as process efficiency and operating costs.
The project is intended to enhance process understanding, inform a planned technology transfer to NurExone’s U.S. subsidiary Exo-Top, and identify opportunities to improve manufacturing efficiency and product consistency. According to NurExone, this work supports the company’s 2026 focus on commercial and clinical readiness for its lead candidate ExoPTEN, which has shown strong preclinical data in acute spinal cord and optic nerve damage and is advancing toward U.S. and European clinical trials under Orphan Drug Designation.
NurExone (TSXV: NRX, OTCQB: NRXBF, FSE: J90) has appointed David Stolick to its Board of Directors effective July 28, 2026, succeeding the late James “Jay” Richardson. Stolick brings finance, capital markets, M&A and healthcare leadership experience from roles at V-Wave, Exalenz Bioscience, BrainStorm Cell Therapeutics and M-Systems.
The company also entered an investor awareness engagement with Cashu Technologies running to no later than December 31, 2026. Cashu will receive US$2,500 per month and may earn an optional US$20,000–US$40,000 one-time fee, payable only in cash, subject to TSX Venture Exchange acceptance.
NurExone (OTCQB: NRXBF) closed a non-brokered private placement of 1,012,573 units at C$0.62 per unit, raising about C$627,795 in gross proceeds, subject to TSXV approval.
Each unit includes one share and one warrant at C$0.78, exercisable for 36 months, with an acceleration feature.
NurExone (OTCQB: NRXBF) announced that its U.S. subsidiary Exo-Top signed a binding MOU with ExoLyra for exclusive distribution of naïve MSC-derived exosome products in Mexico and potential expansion to Brazil and Panama.
Terms include up to 10-year exclusivity, US$180,000 upfront fees, US$800,000 funded launch, annual maintenance fees, and escalating minimum purchase commitments up to 70,000 units per year.
NurExone (OTCQB: NRXBF) reported Q1 2026 results and corporate milestones. Net loss was US$1.77 million, with R&D expenses of US$0.63 million and G&A of US$1.13 million.
The company raised about US$642 thousand via a private placement, advanced CMC readiness with positive proteomic data, executed a U.S.-focused sublicense, and reported new Australian and Korean IP protection for its exosome platform and ExoPTEN candidate.
NurExone (OTCQB: NRXBF) received a South Korean Notice of Patent Grant covering ExoPTEN, its lead exosome-based therapy candidate. The patent protects use of exosomes to deliver PTEN-targeted cargo for nerve injury treatment.
This grant adds to ExoPTEN patents in the US, Japan, Israel and Russia, alongside pending applications in the EU, China and other regions, and complements broader patents on extracellular vesicle production technologies.
NurExone (OTCQB: NRXBF), a biopharmaceutical company focused on exosome-based regenerative therapies for central nervous system injuries, has advanced to Stage 2 of the EU-backed EIT Health Catapult Programme 2026.
Selection was based on its regenerative medicine platform, preclinical data, and regulatory progress, and includes training, mentoring, investor exposure, and pitch events in October 2026.
NurExone (TSXV: NRX / OTCQB: NRXBF) announced that Australian Patent No. 2020303456 covering “Production of extracellular vesicles from stem cells” was granted on April 23, 2026 and is held by Technion Research and Development Foundation.
The patent is licensed exclusively to NurExone, expected to remain in force until June 10, 2040, and expands the company’s international patent family following prior grants in Israel and the United States. Separately, NurExone-backed preclinical data on ExoPTEN for optic nerve regeneration will be presented May 2, 2026 at ISCEV@Denver by Sheba Medical Center researchers.
NurExone (OTCQB: NRXBF) reported FY2025 results and a corporate update on April 16, 2026. Key developments include advancement of lead program ExoPTEN toward IND-enabling work, establishment of U.S. subsidiary Exo-Top, acquisition of a Master Cell Bank, and financing that generated approximately US$5.9M.
FY2025 highlights: R&D $2.64M, G&A $3.69M, net loss $6.38M, cash & equivalents $2.14M, and accumulated deficit $25.48M. A non-binding LOI with BioXtek was announced April 7, 2026.
NurExone (OTCQB: NRXBF) announced that CEO Dr. Lior Shaltiel will speak at the Water Tower Research Insights Conference on April 14, 2026 at 11:50 a.m. ET. The virtual discussion will cover the company's exosome-based therapeutic platform, recent corporate developments, and strategic priorities.